Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Change in Account Payables: 2012-2024

Historic Change in Account Payables for Coherus Oncology (CHRS) over the last 13 years, with Dec 2024 value amounting to -$3.9 million.

  • Coherus Oncology's Change in Account Payables rose 69.61% to -$15.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.1 million, marking a year-over-year increase of 26.56%. This contributed to the annual value of -$3.9 million for FY2024, which is 116.57% down from last year.
  • Coherus Oncology's Change in Account Payables amounted to -$3.9 million in FY2024, which was down 116.57% from $23.8 million recorded in FY2023.
  • In the past 5 years, Coherus Oncology's Change in Account Payables registered a high of $23.8 million during FY2023, and its lowest value of -$9.8 million during FY2020.
  • Moreover, its 3-year median value for Change in Account Payables was -$3.9 million (2024), whereas its average is $5.1 million.
  • Per our database at Business Quant, Coherus Oncology's Change in Account Payables crashed by 620.37% in 2022 and then surged by 622.43% in 2023.
  • Coherus Oncology's Change in Account Payables (Yearly) stood at -$9.8 million in 2020, then skyrocketed by 108.90% to $874,000 in 2021, then tumbled by 620.37% to -$4.5 million in 2022, then soared by 622.43% to $23.8 million in 2023, then tumbled by 116.57% to -$3.9 million in 2024.